Europe Generic Drugs Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034)
Description
The Europe generic drugs market was valued at USD 87.50 Billion in 2024 was driven by rising healthcare needs and the growing demand for cost-effective medications across the region. It is expected to grow at a CAGR of 7.00% during the forecast period of 2025-2034, with the values likely to attain USD 172.13 Billion by 2034.
Europe Generic Drugs Market Analysis
Generic drugs have the same active ingredients as present in the brand-name drugs. They are usually marketed at a lower cost, making them a cost-effective alternative to achieve substantial reductions in medical expenses. Generic pharmaceutical manufacturers must prove the bioequivalence of their version of a drug to a health regulatory agency such as the European Medicines Agency (EMA) for marketing authorization. The increasing government initiatives and the ongoing efforts to establish regulatory reforms that promote the use of generic medications are significantly contributing to the Europe generic drugs market growth.
In Europe, the rising healthcare needs which can be attributed to the growing prevalence of chronic diseases and increasing aging population size are stimulating the global generic drugs market expansion. Recent data reveals that over 9 million adults will be affected by a major illness in England by 2040, accounting for 1 in 5 adults suffering from a health issue. Further, it is estimated that ill health will increase by 2.5 million in the adult population over the two decades from 2019, including a rise in the prevalence of cancer, diabetes, or kidney disease, by more than 30%. Thus, with the growing burden of chronic conditions, the need for affordable generic drugs is expected to fuel in the coming years. Additionally, th growth in the elderly population, as evidenced by one-fifth (21.3%) of the European Union population estimated to be aged 65 years and over in January 2023, is anticipated to augment the Europe generic drugs market demand in the forecast period.
One of the major market trends is the rise in patent expiration of branded drugs that allow generic drug manufacturers to produce and market a bioequivalent version of the same drug at a cheaper price. In 2024, Europe is reported to lose the market exclusivity of a wide range of drugs. Around 73 such drug patents across diverse therapeutic categories including established medications like Cabometyx (anti-cancer medication) and Zavicefta (antibiotic medication for severe bacterial infections) are set to expire, which is poised to significantly influence the market dynamics by facilitating market entry of generic drugs. However, the European market is facing increased generic product recalls, which can be tackled by the introduction of an optimized regulatory framework that ensures sustained growth of the market for generic drugs.
Europe Generic Drugs Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Therapy Area
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Europe Generic Drugs Market Analysis
Generic drugs have the same active ingredients as present in the brand-name drugs. They are usually marketed at a lower cost, making them a cost-effective alternative to achieve substantial reductions in medical expenses. Generic pharmaceutical manufacturers must prove the bioequivalence of their version of a drug to a health regulatory agency such as the European Medicines Agency (EMA) for marketing authorization. The increasing government initiatives and the ongoing efforts to establish regulatory reforms that promote the use of generic medications are significantly contributing to the Europe generic drugs market growth.
In Europe, the rising healthcare needs which can be attributed to the growing prevalence of chronic diseases and increasing aging population size are stimulating the global generic drugs market expansion. Recent data reveals that over 9 million adults will be affected by a major illness in England by 2040, accounting for 1 in 5 adults suffering from a health issue. Further, it is estimated that ill health will increase by 2.5 million in the adult population over the two decades from 2019, including a rise in the prevalence of cancer, diabetes, or kidney disease, by more than 30%. Thus, with the growing burden of chronic conditions, the need for affordable generic drugs is expected to fuel in the coming years. Additionally, th growth in the elderly population, as evidenced by one-fifth (21.3%) of the European Union population estimated to be aged 65 years and over in January 2023, is anticipated to augment the Europe generic drugs market demand in the forecast period.
One of the major market trends is the rise in patent expiration of branded drugs that allow generic drug manufacturers to produce and market a bioequivalent version of the same drug at a cheaper price. In 2024, Europe is reported to lose the market exclusivity of a wide range of drugs. Around 73 such drug patents across diverse therapeutic categories including established medications like Cabometyx (anti-cancer medication) and Zavicefta (antibiotic medication for severe bacterial infections) are set to expire, which is poised to significantly influence the market dynamics by facilitating market entry of generic drugs. However, the European market is facing increased generic product recalls, which can be tackled by the introduction of an optimized regulatory framework that ensures sustained growth of the market for generic drugs.
Europe Generic Drugs Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Therapy Area
- Cardiovascular
- Dermatology
- Respiratory
- Oncology
- Rheumatology
- Others
- Oral
- Injectables
- Dermal/Topical
- Inhalers
- Others
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
- United Kingdom
- Germany
- France
- Others
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Teva Pharmaceutical Industries Ltd
- Viatris Inc.
- Sun Pharmaceutical Industries Ltd
- Lupin
- AstraZeneca
- Baxter
- Takeda Pharmaceutical Company Limited
- GSK plc
- Bausch + Lomb
- Novartis AG
- Sanofi
- Pfizer Inc.
- Fresenius SE & Co. KGaA
- Hikma Pharmaceuticals PLC
- Aurobindo Pharma
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Europe Generic Drugs Market Overview
- 3.1 Europe Generic Drugs Market Historical Value (2018-2024)
- 3.2 Europe Generic Drugs Market Forecast Value (2025-2034)
- 4 Europe Generic Drugs Market Landscape*
- 4.1 Europe Generic Drugs: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Europe Generic Drugs: Product Landscape
- 4.2.1 Analysis by Therapy Area
- 4.2.2 Analysis by Route of Administration
- 4.2.3 Analysis by Distribution Channels
- 5 Europe Generic Drugs Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Europe Generic Drugs Market Segmentation (218-2034)
- 6.1 Europe Generic Drugs Market (2018-2034) by Therapy Area
- 6.1.1 Market Overview
- 6.1.2 Cardiovascular
- 6.1.3 Dermatology
- 6.1.4 Respiratory
- 6.1.5 Oncology
- 6.1.6 Rheumatology
- 6.1.7 Others
- 6.2 Europe Generic Drugs Market (2018-2034) by Route of Administration
- 6.2.1 Market Overview
- 6.2.2 Oral
- 6.2.3 Injectables
- 6.2.4 Dermal/Topical
- 6.2.5 Inhalers
- 6.2.6 Others
- 6.3 Europe Generic Drugs Market (2018-2034) by Distribution Channels
- 6.3.1 Market Overview
- 6.3.2 Hospital Pharmacy
- 6.3.3 Retail Pharmacy
- 6.3.4 Online Pharmacy
- 6.3.5 Others
- 6.4 Europe Generic Drugs Market (2018-2034) by Country
- 6.4.1 Market Overview
- 6.4.2 United Kingdom
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 Others
- 7 United Kingdom Generic Drugs Market Segmentation (218-2034)
- 7.1 United Kingdom Generic Drugs Market (2018-2034) by Therapy Area
- 7.1.1 Market Overview
- 7.1.2 Cardiovascular
- 7.1.3 Dermatology
- 7.1.4 Respiratory
- 7.1.5 Oncology
- 7.1.6 Rheumatology
- 7.1.7 Others
- 7.2 United Kingdom Generic Drugs Market (2018-2034) by Route of Administration
- 7.2.1 Market Overview
- 7.2.2 Oral
- 7.2.3 Injectables
- 7.2.4 Dermal/Topical
- 7.2.5 Inhalers
- 7.2.6 Others
- 8 Germany Generic Drugs Market Segmentation (218-2034)
- 8.1 Germany Generic Drugs Market (2018-2034) by Therapy Area
- 8.1.1 Market Overview
- 8.1.2 Cardiovascular
- 8.1.3 Dermatology
- 8.1.4 Respiratory
- 8.1.5 Oncology
- 8.1.6 Rheumatology
- 8.1.7 Others
- 8.2 Germany Generic Drugs Market (2018-2034) by Route of Administration
- 8.2.1 Market Overview
- 8.2.2 Oral
- 8.2.3 Injectables
- 8.2.4 Dermal/Topical
- 8.2.5 Inhalers
- 8.2.6 Others
- 9 France Generic Drugs Market Segmentation (218-2034)
- 9.1 France Generic Drugs Market (2018-2034) by Therapy Area
- 9.1.1 Market Overview
- 9.1.2 Cardiovascular
- 9.1.3 Dermatology
- 9.1.4 Respiratory
- 9.1.5 Oncology
- 9.1.6 Rheumatology
- 9.1.7 Others
- 9.2 France Generic Drugs Market (2018-2034) by Route of Administration
- 9.2.1 Market Overview
- 9.2.2 Oral
- 9.2.3 Injectables
- 9.2.4 Dermal/Topical
- 9.2.5 Inhalers
- 9.2.6 Others
- 10 Regulatory Framework
- 10.1 Regulatory Overview
- 10.1.1 EU EMA
- 11 Patent Analysis
- 11.1 Analysis by Type of Patent
- 11.2 Analysis by Publication year
- 11.3 Analysis by Issuing Authority
- 11.4 Analysis by Patent Age
- 11.5 Analysis by CPC Analysis
- 11.6 Analysis by Patent Valuation
- 11.7 Analysis by Key Players
- 12 Grants Analysis
- 12.1 Analysis by Year
- 12.2 Analysis by Amount Awarded
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Grant Housing Material
- 12.5 Analysis by Funding Institute
- 12.6 Analysis by Departments
- 12.7 Analysis by Recipient Organization
- 13 Funding and Investment Analysis
- 13.1 Analysis by Funding Instances
- 13.2 Analysis by Type of Funding
- 13.3 Analysis by Funding Amount
- 13.4 Analysis by Leading Players
- 13.5 Analysis by Leading Investors
- 13.6 Analysis by Geography
- 14 Partnership and Collaborations Analysis
- 14.1 Analysis by Partnership Instances
- 14.2 Analysis by Type of Partnership
- 14.3 Analysis by Leading Players
- 14.4 Analysis by Geography
- 15 Supplier Landscape
- 15.1 Market Share by Top 5 Companies
- 15.2 Teva Pharmaceutical Industries Ltd
- 15.2.1 Financial Analysis
- 15.2.2 Product Portfolio
- 15.2.3 Demographic Reach and Achievements
- 15.2.4 Mergers and Acquisitions
- 15.2.5 Certifications
- 15.3 Viatris Inc.
- 15.3.1 Financial Analysis
- 15.3.2 Product Portfolio
- 15.3.3 Demographic Reach and Achievements
- 15.3.4 Mergers and Acquisitions
- 15.3.5 Certifications
- 15.4 Sun Pharmaceutical Industries Ltd
- 15.4.1 Financial Analysis
- 15.4.2 Product Portfolio
- 15.4.3 Demographic Reach and Achievements
- 15.4.4 Mergers and Acquisitions
- 15.4.5 Certifications
- 15.5 Lupin
- 15.5.1 Financial Analysis
- 15.5.2 Product Portfolio
- 15.5.3 Demographic Reach and Achievements
- 15.5.4 Mergers and Acquisitions
- 15.5.5 Certifications
- 15.6 AstraZeneca
- 15.6.1 Financial Analysis
- 15.6.2 Product Portfolio
- 15.6.3 Demographic Reach and Achievements
- 15.6.4 Mergers and Acquisitions
- 15.6.5 Certifications
- 15.7 Baxter
- 15.7.1 Financial Analysis
- 15.7.2 Product Portfolio
- 15.7.3 Demographic Reach and Achievements
- 15.7.4 Mergers and Acquisitions
- 15.7.5 Certifications
- 15.8 Takeda Pharmaceutical Company Limited
- 15.8.1 Financial Analysis
- 15.8.2 Product Portfolio
- 15.8.3 Demographic Reach and Achievements
- 15.8.4 Mergers and Acquisitions
- 15.8.5 Certifications
- 15.9 GSK plc
- 15.9.1 Financial Analysis
- 15.9.2 Product Portfolio
- 15.9.3 Demographic Reach and Achievements
- 15.9.4 Mergers and Acquisitions
- 15.9.5 Certifications
- 15.10 Bausch + Lomb
- 15.10.1 Financial Analysis
- 15.10.2 Product Portfolio
- 15.10.3 Demographic Reach and Achievements
- 15.10.4 Mergers and Acquisitions
- 15.10.5 Certifications
- 15.11 Novartis AG
- 15.11.1 Financial Analysis
- 15.11.2 Product Portfolio
- 15.11.3 Demographic Reach and Achievements
- 15.11.4 Mergers and Acquisitions
- 15.11.5 Certifications
- 15.12 Sanofi
- 15.12.1 Financial Analysis
- 15.12.2 Product Portfolio
- 15.12.3 Demographic Reach and Achievements
- 15.12.4 Mergers and Acquisitions
- 15.12.5 Certifications
- 15.13 Pfizer Inc.
- 15.13.1 Financial Analysis
- 15.13.2 Product Portfolio
- 15.13.3 Demographic Reach and Achievements
- 15.13.4 Mergers and Acquisitions
- 15.13.5 Certifications
- 15.14 Fresenius SE & Co. KGaA
- 15.14.1 Financial Analysis
- 15.14.2 Product Portfolio
- 15.14.3 Demographic Reach and Achievements
- 15.14.4 Mergers and Acquisitions
- 15.14.5 Certifications
- 15.15 Hikma Pharmaceuticals PLC
- 15.15.1 Financial Analysis
- 15.15.2 Product Portfolio
- 15.15.3 Demographic Reach and Achievements
- 15.15.4 Mergers and Acquisitions
- 15.15.5 Certifications
- 15.16 Aurobindo Pharma
- 15.16.1 Financial Analysis
- 15.16.2 Product Portfolio
- 15.16.3 Demographic Reach and Achievements
- 15.16.4 Mergers and Acquisitions
- 15.16.5 Certifications
- 16 Europe Generic Drugs Market – Distribution Model (Additional Insight)
- 16.1 Overview
- 16.2 Potential Distributors
- 16.3 Key Parameters for Distribution Partner Assessment
- 17 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 18 Company Competitiveness Analysis (Additional Insight)
- 18.1 Very Small Companies
- 18.2 Small Companies
- 18.3 Mid-Sized Companies
- 18.4 Large Companies
- 18.5 Very Large Companies
- 19 Payment Methods (Additional Insight)
- 19.1 Government Funded
- 19.2 Private Insurance
- 19.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
